Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... , New GeneConnection discovery microarrays provide more than 4,000 unique,human cDNA sequences ... a series of human cDNA microarrays on , ... which are based on the technology published by Schena et , ... monitoring RNA expression levels , of genes. ...
... with standardized clones , , Rebecca L. ... Wynne Vilma Nioko ,Leonardo DeLeon SanDEe Soares ... Spencer Stevens Chris Hansen Brian Schilling ,Phenogenex ... a single dual- expression vector. These clones eliminate the ...
... fast and easy detection of mycoplasma,contamination , ... Staggs ,Genetic Applications LLC , Heinz Miller ,Stratagene , ... potency of transfection reagents. 1 Cells must be ... ,transfection reagent and ...
Cached Biology Technology:Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and,Discover New Genes 2Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and,Discover New Genes 3Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and,Discover New Genes 4Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 2Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 3Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 4Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 5Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 6Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3
(Date:9/18/2014)... a small, icy moon of Uranus, is one of ... solar system. Despite its relatively small size, Miranda appears ... resulted in the formation of at least three remarkable ... , These coronae are visible in Miranda,s southern ... across. Arden corona, the largest, has ridges and troughs ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Station ever starts a "frequent flyers" program, fruit flies ... orbiting laboratory has hosted increasing numbers of fruit fly ... space station in April, and another is scheduled launch ... planned to launch in December. , Fruit flies are ... and in space. Model organisms can reveal the basis ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... with dogs and using the latest in imaging software and ... heart specialists have developed a fast and accurate means of ... the coronary arteries. Researchers say it took them less ... echocardiograms currently used to find early warning of vessels more ...
... approach, researchers at Children's Hospital Boston have demonstrated that ... a heart attack and protect the heart from scarring. ... a natural inhibitor of cell division with a naturally ... Together, these two agents enabled heart-muscle cells to multiply ...
... Researchers at the Salk Institute for Biological Studies in collaboration ... took a high resolution "action shot" of a protein switch ... nervous system. Their findings, published in the Dec. 8 issue ... design of small molecule inhibitors to control that switch, a ...
Cached Biology News:Fast test for low blood flow in dogs detects early heart trouble 2Fast test for low blood flow in dogs detects early heart trouble 3Fast test for low blood flow in dogs detects early heart trouble 4Rescuing injured hearts by enhancing regeneration 2Rescuing injured hearts by enhancing regeneration 3Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... converts any scanner into a gel densitometer. ... features, the basic operation simply consists of ... etc.) into pixel density / intensity values ... Turn your scanner into a high ...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... effectively in tubes and 96 well plates. microCLEAN ... one and a half spin DNA cleanup reagent. ... concentrate any type of double stranded DNA, efficiently ... dNTPs (labelled or unlabelled). It is therefore ideally ...
Biology Products: